| OEM | OEM Services Provided |
| Feature | Good stability |
| Classification | Chemicals |
| Advantage | Professional, Fast Delivery, Customizable | Samples | Apply for free，Contact Export Director now ↓ |
Citicoline sodium can gradually restore the function of limbs in hemiplegia caused by cerebral stroke, and can also be used for other functional and consciousness disorders caused by acute injury of the central nervous system, as well as ischemic cerebrovascular disease and vascular dementia.
| Category | Details |
|---|---|
| Chemical Formula | C₁₄H₂₆N₄NaO₁₁P₂ (Sodium salt of cytidine-5′-diphosphocholine) |
| Pharmacological Class | Neuroprotective agent – Enhances phospholipid biosynthesis in neurons |
| Primary Indications | – Cerebrovascular accidents: Post-stroke recovery – Cognitive impairment: Alzheimer’s, vascular dementia – Head trauma: TBI rehabilitation – Glaucoma: Neuroprotective adjunct |
| Mechanism of Action | – Phospholipid precursor: Increases neuronal membrane synthesis – Acetylcholine precursor: Boosts cholinergic neurotransmission – Antioxidant: Reduces free radical damage |
| Pharmacokinetics | – Bioavailability: ~15% (oral) – Half-life: 1.5-3 hours – Metabolism: Hydrolyzed to choline/cytidine – Excretion: Renal (70-80%) |
| Dosage Forms | – Tablets: 500mg, 1000mg – Injections: 500mg/2mL, 1000mg/4mL – Oral solution: 50mg/mL |
| Administration | – Acute phase: IV infusion (1000mg/day) – Maintenance: Oral (500-2000mg/day) – Duration: 6-12 weeks (clinical trials) |
| Adverse Effects | – Mild: Headache, GI disturbance – Rare: Allergic reactions, hypotension – Long-term: Not established (limited data >6 months) |
| Drug Interactions | – Synergistic: Levodopa, donepezil – Caution: Anticholinergics (additive effects) – Monitor: Warfarin (theoretical interaction) |
| Regulatory Status | – FDA: Dietary supplement (NDIN 883) – EMA: Orphan drug designation (2008) – Japan: Approved for dementia (2011) |
| Market Trends | – Aging populations: Rising demand for cognitive enhancers – Combination therapies: With cholinesterase inhibitors – Emerging markets: Asia-Pacific growth (2023-2028 CAGR ~7.2%) |
Note: Clinically studied for neuroplasticity enhancement. Requires controlled trials to validate long-term efficacy in chronic neurodegeneration.
,Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
Declaration: The products displayed on this website are intended exclusively for industrial applications or scientific research. They are not intended for medical, pharmaceutical, or food use. In accordance with applicable laws and regulations, purchasing organizations must hold valid qualifications and approvals.
For help with solutions customized to your business needs, contact Export Director now.
With 30+ years of experience and We firmly believe that product quality is the basis of cooperation.
Chat Now
TEl
+86-21-6420 0566
